These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3284877)

  • 1. Effect of tyrosine on attention deficit disorder with hyperactivity.
    Eisenberg J; Asnis GM; van Praag HM; Vela RM
    J Clin Psychiatry; 1988 May; 49(5):193-5. PubMed ID: 3284877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary study of the relationship between central auditory processing disorder and attention deficit disorder.
    Cook JR; Mausbach T; Burd L; Gascon GG; Slotnick HB; Patterson B; Johnson RD; Hankey B; Reynolds BW
    J Psychiatry Neurosci; 1993 May; 18(3):130-7. PubMed ID: 8499429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid precursors for the treatment of attention deficit disorder, residual type.
    Wood DR; Reimherr FW; Wender PH
    Psychopharmacol Bull; 1985; 21(1):146-9. PubMed ID: 3885291
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for megavitamin therapy in the treatment of attention deficit hyperactivity disorder?
    Haslam RH
    Adv Neurol; 1992; 58():303-10. PubMed ID: 1414636
    [No Abstract]   [Full Text] [Related]  

  • 10. Addressing comorbidity in adults with attention-deficit/hyperactivity disorder.
    Hornig M
    J Clin Psychiatry; 1998; 59 Suppl 7():69-75. PubMed ID: 9680055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenfluramine treatment of childhood attention deficit disorder with hyperactivity: a preliminary report.
    Donnelly M; Rapoport JL; Ismond DR
    Psychopharmacol Bull; 1986; 22(1):152-4. PubMed ID: 3523573
    [No Abstract]   [Full Text] [Related]  

  • 13. Bupropion in children with attention deficit disorder.
    Casat CD; Pleasants DZ; Schroeder DH; Parler DW
    Psychopharmacol Bull; 1989; 25(2):198-201. PubMed ID: 2513592
    [No Abstract]   [Full Text] [Related]  

  • 14. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type.
    Reimherr FW; Wender PH; Wood DR; Ward M
    Am J Psychiatry; 1987 Aug; 144(8):1071-3. PubMed ID: 3300376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of two rating scales for attention-deficit hyperactivity disorder diagnosis in Colombian children.
    Pineda DA; Aguirre DC; Garcia MA; Lopera FJ; Palacio LG; Kamphaus RW
    Pediatr Neurol; 2005 Jul; 33(1):15-25. PubMed ID: 15993319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Attention-deficit/hyperactivity disorder (ADHS) in adulthood].
    Kordon A; Kahl KG
    Psychother Psychosom Med Psychol; 2004; 54(3-4):124-36. PubMed ID: 15037976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open trial of buspirone in the treatment of attention-deficit disorder.
    Niederhofer H
    Hum Psychopharmacol; 2003 Aug; 18(6):489-92. PubMed ID: 12923830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginkgo biloba treating patients with attention-deficit disorder.
    Niederhofer H
    Phytother Res; 2010 Jan; 24(1):26-7. PubMed ID: 19441138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blink rate in children with attention-deficit-hyperactivity disorder.
    Caplan R; Guthrie D; Komo S
    Biol Psychiatry; 1996 Jun; 39(12):1032-8. PubMed ID: 8780838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.